Research and Markets: Atherosclerosis - Pipeline Review, H2 2014

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/rs5fhq/atherosclerosis) has announced the addition of the "Atherosclerosis - Pipeline Review, H2 2014" report to their offering.

This report provides comprehensive information on the therapeutic development for Atherosclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atherosclerosis and special features on late-stage and discontinued projects.

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Atherosclerosis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Atherosclerosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned:

  • Aastrom Biosciences, Inc.
  • Ache Laboratorios Farmaceuticos S/A
  • advanceCor GmbH
  • AFFiRiS AG
  • Arisaph Pharmaceuticals, Inc.
  • Artery Therapeutics, Inc.
  • AstraZeneca PLC
  • Athera Biotechnologies AB
  • AtheroNova Inc.
  • AuraSense Therapeutics, LLC
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bridge Bioresearch Plc
  • Bristol-Myers Squibb Company
  • Cardax Pharmaceuticals, Inc.
  • ChemoCentryx, Inc.
  • CIMAB S.A.
  • CSL Limited
  • DoNatur GmbH
  • Dr. Reddy's Laboratories Limited
  • Dybly AG
  • GlaxoSmithKline plc
  • Isis Pharmaceuticals, Inc.
  • Johnson & Johnson
  • KineMed, Inc.
  • Kowa Company, Ltd.
  • Lead Discovery Center GmbH
  • MedImmune, LLC
  • Zydus Cadila Healthcare Limited

For more information visit http://www.researchandmarkets.com/research/rs5fhq/atherosclerosis

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Cardiovascular

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Cardiovascular